Ribomic, Inc. (JP:4591)
:4591
Want to see JP:4591 full AI Analyst Report?
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥57.00 - ¥127.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)477.44K
Market Cap
¥3.53B
Enterprise Value¥1.55B
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.34
Shares Outstanding55,972,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)1.54
Price to Sales (P/S)1456.29
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero total debt and a net-cash posture materially lower near-term financing risk and provide a durable buffer to support ongoing R&D and collaborations. This structural strength buys runway for 2–6 months+ of development activities without immediate refinancing stress.
Revenue ReboundA reported ~42% revenue increase signals improving commercial traction from licensing, milestones, or partnerships. Durable multi-period revenue growth supports scaling of collaborative income streams and validates elements of the business model beyond one-off gains.
Licensing And Partnership ModelA capital-light licensing and milestone-driven model transfers late-stage development and commercialization risk to partners while creating recurring royalty and milestone potential. Structurally this reduces required capex and can generate scalable, less cyclical revenue over time.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicate structural cash burn to fund R&D and operations. Over 2–6 months this necessitates financing or partner income; absent reliable inflows, cash depletion threatens continuity or forces dilutive funding.
Deep Sustained UnprofitabilityLarge recurring operating and net losses show margins are structurally negative versus the current revenue base. Without clear cost reductions or material revenue scaling, profitability appears distant, constraining ability to self-fund development long term.
Eroding Equity BaseDeclining equity despite zero debt reduces the capital cushion available for shocks and investment. Continued erosion limits non-dilutive options and increases reliance on external financing, which can be dilutive or costly and impair long-term shareholder value.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥57.00 and its highest was ¥127.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥3.53B.
When is Ribomic, Inc.’s upcoming earnings report date?
Ribomic, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Ribomic, Inc.’s earnings last quarter?
Ribomic, Inc. released its earnings results on May 14, 2026. The company reported -¥7.21 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.21.
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 55,972,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Ribomic, Inc. reported an EPS of -¥7.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.